The analysis focuses on Hims & Hers Health (HIMS). The stock is currently at $44.46, down approximately 30% over the previous month but up 76% year-to-date. The presenter notes HIMS is trading at roughly three times sales with approximately 54% sales growth and 80% gross margins. A potential lawsuit and related negative media could be ending. The pundit suggests HIMS can obtain a rerating to 6-10 times sales. Expansion into Europe and Canada are also noted. The target price is inferred to be 67.42 with the failure bound set around $40.00. The prediction timeframe is approximately 5 years and the current and predicted trend is that it will become bullish soon.